

Introduction: The patient was a 34-year-old male admitted to the psychiatric inpatient unit for high anxiety and suicide ideation due to severe toothache.

Objectives: To show how the antipsychotic pimozide can be an effective option for the treatment of anxiety and obsessive symptoms around physical complaints within the spectrum of somatoform disorders

Methods: Case report and literature review

Results: The patient comes to the emergency room with high anxiety and active self-harming ideation. He reports that for months he has been experiencing mouth pain that is becoming more and more intense. He has seen multiple professionals without finding a cause that justifies the pain. In the past she has a history of multiple ailments (knee, abdominal pain...). He is being treated with sertraline 150, clonazepam 3 mg per day and olanzapine 5 mg at night. During admission, treatment with pimozide up to 4 mg per day was started. The patient is progressively less distressed and with more distance from the ideas about pain, being able to carry out more activities during the day. There is remission of suicidal ideation

Conclusions: There is evidence in the literature that the use of pimozide was effective in different psychotic disorders. It has been seen to reduce the intensity of symptoms in cases of delusional disorders with delirium of somatic type or those such as delusions by parasitization. The use of pimozide has also been effective in the treatment of complex tic disorder. In this case it is effective and could be explained by the close relationship of osbsesive symptoms with psychotic symptoms.

Disclosure of Interest: None Declared

EPV0082

The Effect of the Apollo Neuro Device on Anxiety Among Participants who Underwent Ketamine Assisted Therapy

V. Tsang

UBC, Vancouver, Canada

doi: 10.1192/j.eurpsy.2024.875

Introduction: The study aimed to evaluate the effectiveness of a device called “Apollo” in reducing anxiety, as compared to a control group. Participants were divided into two groups: the intervention group (receiving the “Apollo” device) and the control group (receiving no intervention).

Objectives: The primary outcome measure was the change in Generalized Anxiety Disorder 7-item (GAD-7) scores, calculated as the difference between post-GAD-7 and pre-GAD-7 scores.

Methods: Participants were recruited from two different cohorts, with the intervention group derived from the “Apollo” dataset and the control group derived from the “KaT Cohort 9” dataset. Matching was performed based on Age, Sex, and pre-GAD-7 scores to create comparable groups.

For those with full datasets, a total of 4 (out of 5) participants from the “Apollo” group were matched with 15 (out of 45) participants from the “Control” group, based on the selected criteria. Data cleaning was performed to handle missing values and non-numeric entries. Propensity score matching was used to match participants from the “Apollo” and “Control” groups based on Age, Sex, and pre-GAD-7 scores. An independent samples t-test was conducted to compare the mean change in GAD-7 scores between the two groups. Since propensity score matching requires complete data on

matching factors (age, sex, pre-GAD-7), those without full datasets were excluded.

Results: The median change in GAD-7 scores in the “Apollo” group was -8.5 , indicating a median reduction in anxiety symptoms. The independent samples t-test revealed no statistically significant difference in the change in GAD-7 scores between the “Apollo” and “Control” groups ($t = -0.889$, $p = 0.387$). Therefore, the study so far did not conclude a significant difference.

Conclusions: Ketamine assisted therapy remains a promising way to decrease anxiety among patients with generalized anxiety disorder and elevated GAD-7 scores. Ways to potentially improve these results are increasing the number of Apollo patients and having more balanced numbers between groups.

Disclosure of Interest: None Declared

EPV0085

Cannabis Use and Its Interaction with Anxiety Disorders

F. Varino*, T. Duarte, F. S. Silva, P. Froes, A. M. Fernandes and P. Baronet

Psychiatry, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal

*Corresponding author.

doi: 10.1192/j.eurpsy.2024.876

Introduction: Cannabis use has been reported to cause a myriad of acute adverse reactions, including those linked to anxiety disorders, such as panic attacks and derealization. Notably, in the emergency department, anxiety makes up a significant proportion of the complaints related to cannabinoid consumption. Several reports show these symptoms can persist after the cessation of cannabis consumption. Consequently, some questions have arisen regarding the role of cannabinoids as precipitators for anxiety disorders in vulnerable individuals. Alternatively, it has been hypothesized that patients with anxiety disorders are more prone to using cannabis.

Objectives: We aim to understand whether there is an established relationship between anxiety disorders and cannabis use. Moreover, we intend to identify what are the factors which make an individual more likely to experience anxiety following cannabis consumption.

Methods: A search was conducted in the PubMed database using the MeSH terms “cannabis”, “panic disorder”, “anxiety”, “panic” and “generalized anxiety disorder”. Articles published in the last ten years were considered. Publications were selected after careful reading of their abstract. A non-systematic review of the selected articles was performed.

Results: Eight articles were included in this review. While a majority of these publications did not find a significant association between cannabis use and anxiety disorders, a small subset of analyzed articles found that cannabis use may increase anxiety severity in general, devoid of specific diagnostic association. Individuals who presented to the emergency department with anxiety complaints after cannabis use were likely to be young and to have ingested edible cannabis. History of psychiatric disease, especially substance use disorder, was common in this population.

Conclusions: Most available data suggest cannabis use is not clearly linked to anxiety disorders. However, information around this topic is scarce and heterogenous. Further research is needed focusing on the natural evolution of acute anxiety after cannabis use. Factors such as young age, presence of psychiatric comorbidities and

consumption of edible cannabis appear to contribute to a significantly increased risk of experiencing acute anxiety after cannabis use.

Disclosure of Interest: None Declared

EPV0086

Role of Virtual Reality in Treating Anxiety in Child & Adolescent

K. Shah^{1*}, P. Reddy², A. Giri³ and S. Srinivas⁴

¹Wake Forest University; ²Baptist Health - UAMS Medical Education Program PGY-4 Psychiatry Resident; ³Dhaka University and ⁴Baptist Health and the University of Arkansas for Medical Sciences (BH-UAMS), Winston-Salem, United States

*Corresponding author.

doi: 10.1192/j.eurpsy.2024.877

Introduction: Anxiety disorder affects nearly 9.4% of children aged 3-17 years.1 Virtual Reality (VR) provides an alternative for managing anxiety due to immersive, multisensory, and excellent distraction.

Objectives: The aim is to evaluate the efficacy of VR therapy in managing anxiety in children.

Methods: We searched PubMed, Medline, Embase, Web of Science, and Biosisdatabases with the keywords "Virtual Reality" in the context of "AnxietyDisorders" and included 8 relevant studies published in English until February 10, 2023, for our qualitative synthesis.

Results: The VR-Guided relaxation (VR-GR) effectively decreased anxiety immediately after administration. In another trial, 4 of the 9 patients completely overcame their fears, and 8 of 9 saw an improvement in target behaviors in the autism population even after six weeks after the therapy, and the effect lasted 1 year post-treatment. In another study, VR-based therapy helped reduce anxiety and behavioral scores significantly in the VR group vs. the control. In another study, they found during pediatric intravenous catheter placement, patients who received VR therapy showed significantly less anxiety and pain compared to those who did not. In another study, they found VR therapy helped reduce anxiety during the induction of pre-operative anesthesia in children undergoing elective surgery.

Conclusions: A study discovered benefits with statistically significant results in reducing anxiety in children immediately after VR-based therapy. To explore the full spectrum of benefits and efficacy of VR-based therapy for anxiety as a standalone or adjunct to pharmacotherapy, we recommend future trials with robust study designs.

Disclosure of Interest: None Declared

EPV0087

Results of anxiety disorders in a medical professional

P. Sarantuya^{1*}, B. Putev¹ and T. Myatav²

¹Medical department, Etugen university and ²Avicenna science center, Ulaanbaatar, Mongolia

*Corresponding author.

doi: 10.1192/j.eurpsy.2024.878

Introduction: Anxiety is the most prevalent disease in the world. Symptoms of anxiety disorders affect everyone. The symptoms are worse after a long period of time and more severe disease than normal. A study was conducted to support the assumption that it is an opportunity to improve healthcare services.

Objectives:

1. Anxiety disorders of doctors and medical specialists of Selenge Province General Hospital
2. Determine the relationship between certain factors and certain factors of anxiety disorders

Methods: The GAD7, SRQ20, and PHQ9, sleep system detection questionnaire methods issued by WHO for doctors of primary health care institutions were analyzed by analytical research snapshot model from 03.15 to 04.05, 2023.03.22. /1/01 was obtained and the survey was conducted.

Results: In the study, 23-65-year-olds received medical care, and the average life expectancy was 37.05 years. 30% (27) of the respondents did not have anxiety disorders, 36.67% (33) had mild anxiety disorders, 18.89% (17) had moderate anxiety disorders, and 14.44% (13) had severe health problems. 6.67% (6) of the respondents had no depression, 10% (9) had very mild depression and could cope on their own, 24.44% (22) had moderate depression and could cope, and 27.78% (25) with healthy depression. 24.44% (22) had major depressive disorder and 6.67% (6) had major depressive disorder. According to correlation analysis, GAD7 score with SRQ20 stress score $r=0.76$ and PHQ9 mood score with $r=0$. the inverse association was statistically significant at $p=0.00$. PHQ9 depression score had a strong effect on SRQ20 stress score $r=0.74$, $p=0.00$, and GAD7 score $r =0.46$, $p=0.0000$. $r=-0.40$, $p=0.00$ had a moderate inverse relationship with age, and $r=-0.24$, $p=0.00$ had a weak inverse relationship with age. In linear regression analysis, the GAD7 anxiety disorder score increased by 48.8% ($p=0.00$) when fixed at one, which was statistically significant. In logistic regression analysis, PHQ9 depression score increased by 35.08% ($p=0.01$) per entry. In composite logistic regression analysis, the PHQ9 depression score was statistically significant $OR=4.07$ ($p=0.01$) multiplied by one.

Conclusions: Doctors and medical professionals include psychological health research, testing, treatment, psychological counseling, and health care. Anxiety disorders are related to stress, depression, satisfaction, and age, while depressive disorders are anxiety disorders.

Disclosure of Interest: None Declared

EPV0088

Features of cognitive functions in generalized anxiety disorder: narrative review

E. L. Isakulyan^{1*} and M. P. Marachev^{1,2}

¹Neurocenter of medical and psychological correction and rehabilitation and ²Moscow Scientific Research Institute of Psychiatry Branch of V. Serbsky National Medical Research Centre for Psychiatry and Narcology, Moscow, Russian Federation

*Corresponding author.

doi: 10.1192/j.eurpsy.2024.879

Introduction: Generalized anxiety disorder (GAD) is characterized by excessive and uncontrollable worry and anxiety about several activities or events. Although some cognitive symptoms are common in GAD patients, there are still controversial results from their linkage. Some studies indicate intact cognitive functions in GAD patients, while others suggest that anxiety and its cognitive aspect, worry, are associated with reduced performance in several cognitive domains.